These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16181425)

  • 1. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Bailey CD; Rogers DA; Johnson GV; Hayden MR; Leavitt BR
    J Neurochem; 2005 Oct; 95(1):210-20. PubMed ID: 16181425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
    Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
    Chen S; Zhang XJ; Xie WJ; Qiu HY; Liu H; Le WD
    CNS Neurosci Ther; 2015 Aug; 21(8):662-71. PubMed ID: 26122704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
    Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
    Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
    Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR
    Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
    Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
    J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
    Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
    BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Lu G; Barakauskas VE; Barr AM; Honer WG; Hayden MR; Leavitt BR
    Exp Neurol; 2005 Dec; 196(2):266-72. PubMed ID: 16129433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
    Xie Y; Hayden MR; Xu B
    J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
    Sivananthan SN; Leavitt BR
    Neurobiol Aging; 2011 Dec; 32(12):2326.e1-4. PubMed ID: 21741126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
    Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
    Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
    Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
    Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of cystamine in a murine model of Huntington's disease.
    Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
    J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential changes in thalamic and cortical excitatory synapses onto striatal spiny projection neurons in a Huntington disease mouse model.
    Kolodziejczyk K; Raymond LA
    Neurobiol Dis; 2016 Feb; 86():62-74. PubMed ID: 26621114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
    Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
    J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.
    Wang X; Sarkar A; Cicchetti F; Yu M; Zhu A; Jokivarsi K; Saint-Pierre M; Brownell AL
    J Neurol Sci; 2005 Apr; 231(1-2):57-66. PubMed ID: 15792822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
    Garcia-Miralles M; Geva M; Tan JY; Yusof NABM; Cha Y; Kusko R; Tan LJ; Xu X; Grossman I; Orbach A; Hayden MR; Pouladi MA
    JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.